Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
P/E ratio for Medpace Holdings, Inc. (MEDP)
P/E ratio as of 2023: 33.30
According to Medpace Holdings, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 33.30. At the end of 2022 the company had a P/E ratio of 28.06.
P/E ratio history for Medpace Holdings, Inc. from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 33.30 |
| 2022 | 28.06 |
| 2021 | 43.03 |
| 2020 | 34.23 |
| 2019 | 30.11 |
| 2018 | 25.81 |
| 2017 | 36.28 |
| 2016 | 96.13 |
| 2015 | -126.99 |
| 2014 | -52.53 |
| 2013 | 42.89 |